Asbestos and Mesothelioma Claims: What the Litigation Record Shows

Asbestos is a naturally occurring mineral fiber that US agencies classify as a known human carcinogen. Inhaling asbestos fibers can cause mesothelioma, a cancer of the thin membranes lining the chest and abdomen, along with cancers of the lung, larynx and ovary and the non-cancerous lung disease asbestosis. The legal response has no single ending: claims have been filed in US courts since the 1960s, many manufacturers resolved liability through bankruptcy trusts, and the federal courts have not handled asbestos claims in one continuing consolidated proceeding. The agency record establishes that asbestos causes disease. In the sources cited here, no court has decided that any individual defendant’s product caused any individual person’s illness.

What asbestos is, and how exposure is regulated

Asbestos occurs in rock and soil. Its strength and heat resistance led to wide use in insulation, floor and ceiling tiles, pipe wrap, brakes and clutches, gaskets and heat-resistant fabrics. Fibers are released when asbestos-containing material is disturbed during demolition, repair or renovation (EPA, Learn About Asbestos). CDC’s NIOSH links asbestos exposure to lung cancer, asbestosis and mesothelioma.

Regulation is split between two agencies. OSHA sets workplace exposure standards and states that there is no safe level of asbestos exposure for any fiber type. EPA regulates asbestos in buildings, drinking water and air under the Toxic Substances Control Act, and protects state and local employees not covered by an OSHA-approved state plan (EPA, Protecting Workers from Asbestos). EPA adds that risk increases with exposure and that symptoms can take many years to appear. The National Cancer Institute puts the interval between exposure and symptoms at 10 to 40 years or more, and notes that people with only brief exposures have developed mesothelioma.

Two dated actions frame the current picture. On March 18, 2024, EPA finalized a rule prohibiting ongoing uses of chrysotile asbestos, the only form then imported into or used in the United States, with transition deadlines for the chlor-alkali sector and for brake, gasket and other friction products. That release notes a 1991 court decision largely struck down EPA’s 1989 ban and weakened its TSCA authority until the 2016 amendments. On November 27, 2024, EPA finalized part two of its TSCA risk evaluation, covering legacy uses such as floor tiles, pipe wraps and insulation plus five additional fiber types, and found an unreasonable risk to human health.

What is established vs. what is alleged

Established by agency findings and court records:

• Asbestos is a known human carcinogen, associated with mesothelioma and cancers of the lung, ovary and larynx, plus asbestosis and other lung conditions (NCI; EPA; CDC/NIOSH).
• Disease can appear long after exposure, and even brief exposures have been linked to mesothelioma (NCI; OSHA).
• Regulators have taken the specific, dated actions described above (EPA).
• Courts centralized federal asbestos pretrial proceedings in 1991 and stopped transferring new tag-along cases after 2011 (JPML; E.D. Pa.).
• The bankruptcy trust system exists, and GAO documented how it works (GAO-11-819).

Alleged, and still contested case by case:

• That a specific defendant’s product exposed a specific person to asbestos.
• That a specific defendant failed to warn or was otherwise negligent.
• What an individual claim is worth, and what caused a claimant’s disease.

Those questions are decided in individual tort cases, through settlement or trial. They are not decided by an agency risk evaluation.

Where asbestos claims stand procedurally

Federal multidistrict litigation. In 1991 the Judicial Panel on Multidistrict Litigation centralized federal asbestos personal injury and wrongful death actions in MDL No. 875, In re: Asbestos Products Liability Litigation (No. VI), in the Eastern District of Pennsylvania. The court’s page states that MDL 875 now consists of about 3,000 transferred cases, each typically with multiple plaintiffs and defendants. In 2012 the Panel adopted the transferee judge’s suggestion and stopped transferring new tag-along actions, finding the backlog largely eliminated and roughly 400 new federal asbestos personal injury cases a year manageable in the district courts (JPML). A proposed nationwide settlement class failed: the Third Circuit rejected it in Georgine v. Amchem Products and the Supreme Court affirmed that ruling in Amchem Products, Inc. v. Windsor (1997) (E.D. Pa.). Later legislative alternatives, including the FAIR Act proposals, did not become law (same source).

Bankruptcy trusts. GAO reported in 2011 that about 100 companies had filed for bankruptcy at least partly because of asbestos liability, and that 60 trusts established since 1988 held about $37 billion in total assets. A company reorganizing under Chapter 11 may channel its asbestos liabilities into a trust under 11 U.S.C. 524(g); the trust then reviews claimants’ occupational and medical histories administratively, outside the court system, and reports annually to the bankruptcy court (GAO-11-819).

CollectiveClaim.us covers these cases as part of its environmental litigation reporting.

Key dates

• 1988: the first of the asbestos personal injury trusts counted by GAO is established (GAO-11-819).
• 1991: the JPML creates MDL No. 875 in the Eastern District of Pennsylvania (JPML).
• 1997: the Supreme Court affirms decertification of the proposed global asbestos settlement class in Amchem (E.D. Pa.).
• September 23, 2011: GAO issues GAO-11-819, counting 60 trusts with about $37 billion in assets (GAO-11-819).
• 2011 to 2012: the JPML terminates new tag-along transfers to MDL 875 (JPML).
• March 18, 2024: EPA bans ongoing uses of chrysotile asbestos (EPA).
• November 27, 2024: EPA finds that asbestos poses an unreasonable risk to human health (EPA).

What this does not establish

• That any named company caused any named person’s disease. An agency hazard finding describes a substance, not a defendant’s liability.
• A national compensation figure or a single settlement. GAO’s trust totals are aggregate assets and payments across many trusts, not the value of any individual claim.
• That regulation ends exposure. The 2024 rule addresses ongoing uses, and EPA’s part two evaluation covers legacy material already in buildings.
• That a claim is timely or that anyone is eligible for payment. That depends on state law, the facts of an exposure, and each trust’s rules.

Frequently asked questions

Does a mesothelioma diagnosis mean a person can sue?

Not by itself. Whether a claim is viable depends on what the person was exposed to and when, which products were involved, and the applicable state law, including filing deadlines. Anyone assessing their own position should consult a lawyer licensed in that state; a state bar referral service or legal aid office is a starting point.

What are asbestos bankruptcy trusts?

They are how a company in bankruptcy resolves present and future asbestos claims. Under 11 U.S.C. 524(g), the company transfers liabilities and certain assets to a trust, which reviews claims administratively instead of through trials. GAO counted 60 trusts holding about $37 billion in assets as of 2011.

Is there one national asbestos lawsuit or settlement?

No. Federal cases were centralized for pretrial purposes in MDL 875 from 1991, transfers of new cases stopped after 2011, and a proposed nationwide settlement class was rejected in Amchem and never revived. Claims now proceed individually in state and federal courts and through the trusts.

Why can claims be filed decades after exposure?

Asbestos-related disease has a long latency period. NCI states that symptoms can take 10 to 40 years or more to appear, and that people with brief exposures have developed mesothelioma. That delay explains the length of the litigation and why filing deadlines depend on when a person was diagnosed (see statute of limitations in injury claims).

Related reading: the AFFF PFAS firefighting foam litigation, the Roundup glyphosate litigation, and how mass tort litigation works.

Sources

1. U.S. Environmental Protection Agency: “Learn About Asbestos” (link, accessed 2026-10-13)
2. U.S. Environmental Protection Agency: “EPA Finalizes Part 2 TSCA Risk Evaluation for Asbestos” (link, accessed 2026-10-13)
3. U.S. Environmental Protection Agency: “Biden-Harris Administration finalizes ban on ongoing uses of asbestos to protect people from cancer” (link, accessed 2026-10-13)
4. U.S. Environmental Protection Agency: “Protecting Workers from Asbestos” (link, accessed 2026-10-13)
5. U.S. Occupational Safety and Health Administration: “Asbestos - Overview” (link, accessed 2026-10-13)
6. National Cancer Institute: “Asbestos Exposure and Cancer Risk” (link, accessed 2026-10-13)
7. Centers for Disease Control and Prevention (NIOSH): “Asbestos” (link, accessed 2026-10-13)
8. U.S. Government Accountability Office: “Asbestos Injury Compensation: The Role and Administration of Asbestos Trusts (GAO-11-819)” (link, accessed 2026-10-13)
9. U.S. District Court for the Eastern District of Pennsylvania: “MDL 875 In Re: Asbestos Products Liability Litigation (No. VI)” (link, accessed 2026-10-13)
10. United States Judicial Panel on Multidistrict Litigation: “Order Adopting Suggestion to the Panel Concerning Future Tag-Along Transfers, MDL No. 875” (link, accessed 2026-10-13)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.